News for 'YMI' - (YM BioSciences Reports Q2 2012 Operational and Financial Results)
Feb 15, 2012 (Close-Up Media via COMTEX) -- YM BioSciences Inc., a drug
development company advancing a diverse portfolio of hematology and cancer
related products, reported operational and financial results for its second
quarter of fiscal 2012, ended December 31, 2011.
"JAK inhibitors may ultimately prove valuable in the treatment of a wide range
of blood disorders, cancers and inflammatory diseases, representing an immense
opportunity for this emerging drug class. We recently reported multicenter data
for our lead JAK inhibitor, CYT387, establishing its competitive safety and
efficacy profile in patients with myelofibrosis," said Dr. Nick Glover,
President and CEO of YM BioSciences. "The strength of our data positions us well
to select the optimal course to further advance this opportunity."
In a release on February 9, the Company reported updated results from the Phase
I/II study of CYT387 in 166 patients with myelofibrosis were presented in a
poster session at the 53rd Annual Meeting of the American Society of Hematology
held in San Diego in December 2011. CYT387 demonstrated an ability to render and
maintain anemic myelofibrosis patients transfusion independent for
clinically-relevant periods while also producing significant and durable
improvements in their splenomegaly and constitutional symptoms. CYT387 was
generally safe and well tolerated in myelofibrosis patients for dosing periods
up to and exceeding two years, with minimal treatment-related myelosuppression
observed.
Financial Results (CDN dollars)
The interim consolidated financial statements and comparative information for
the second quarter of fiscal 2012 have been prepared in accordance with
International Financial Reporting Standards (IFRS). Previously, up to June 30,
2011, the Company prepared its Interim and Annual Consolidated Financial
Statements in accordance with Canadian Generally Accepted Accounting Principles
("Canadian GAAP").
Revenue from out-licensing for the second quarter of fiscal 2012, ended December
31, 2011, was $0.4 million compared with $0.3 million for the second quarter of
fiscal 2011. Revenue from out-licensing for the first six months of fiscal 2012
was $0.6 million and comparable to $0.6 million for the first six months of
fiscal 2011.
Net finance income was $1.5 million for the second quarter of fiscal 2012
compared to net finance costs of $4.6 million for the second quarter of fiscal
2011. Net finance income was $9.0 million for the first six months of fiscal
2012 compared to net finance costs of $8.3 million for the first six months of
fiscal 2011. Under IFRS, warrants denominated in a different currency than the
Company's functional currency must be classified as a financial liability and
measured at fair value, with changes reflected in profit or loss. The change in
net finance income during the second fiscal quarter is primarily attributed to a
change of $6.0 million in the fair value adjustment for USD warrants. For the
first six months of fiscal 2012, the Company incurred a gain of $7.3 million
compared to a loss of $7.5 million for the six months ended December 31, 2010 on
the revaluation of warrants.
Licensing and product development expenses were $7.3 million for the second
quarter of fiscal 2012 compared with $5.2 million for the second quarter of
fiscal 2011. Licensing and product development expenses were $13.7 million for
the first six months of fiscal 2012 compared with $10.9 million for the first
six months of fiscal 2011. Development expenses for CYT387 increased due to the
expansion of the Phase I/II clinical trial in myelofibrosis, start-up costs
associated with the BID (twice-daily dosing) study, pre-clinical development
activities, and manufacturing of drug for these programs. Expenses for
nimotuzumab continued to decrease.
General and administrative expenses were $1.2 million for the second quarter of
fiscal 2012 compared to $2.7 million for the second quarter of fiscal 2011.
General and administrative expenses were $3.3 million for the first six months
of fiscal 2012 compared to $5.0 million for the first six months of fiscal 2011,
primarily due to severance and restructuring costs in 2010.
Net loss for the second quarter of fiscal 2012 was $6.6 million ($0.06 per
share) compared to $12.3 million ($0.14 per share) for the same period last
year.
As at December 31, 2011 the Company had cash and short-term deposits totaling
$67.9 million and accounts payables and accrued liabilities totaling $3.7
million compared to $79.7 million and $4.4 million respectively at June 30,
2011. Management believes that the cash and short-term deposits at December 31,
2011 are sufficient to support the Company's activities for at least the next 18
months.
As at December 31, 2011 the Company had 116,711,448 common shares and 7,366,418
warrants outstanding.
((Comments on this story may be sent to newsdesk@closeupmedia.com))
Harleyman!
